Ben van Hout

Deep Dive

Revealing the true value of new cancer drugs to payers

Marc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new cancer treatments like CAR-T with payers.

News

Ex-BioNTech execs launch 'AI-native' cancer company

Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks